Project Grant R01AG099763
- The National Institute on Drug Abuse awarded Louisiana State University Health Sciences Center New Orleans $723,353 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 1, 2026. The award funds research examining HIV-associated premature aging through cannabinoid-mediated anti-inflammatory mechanisms. The recipient's research team has established an autopsy program studying HIV viral tissue reservoirs and neuropathogenesis in deceased people living with HIV, analyzing...
- The National Institute on Drug Abuse awarded Tulane University (The Administrators of Tulane Educational Fund) $1,002,979 on September 1, 2026, for exploratory studies of HIV infection and pathogenesis in the context of THC use under the Drug Use and Addiction Research Programs (CFDA 93.279). The research investigates whether cannabinoids can reprogram leukocytes and glial cells to less inflammatory phenotypes, potentially reducing central nervous system seeding and persistence of the HIV...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded Tulane University $874,974 on September 1, 2026, under the Aging Research program (CFDA 93.866) to study the effects of CSF1R blockade on brain aging and HIV-associated neurocognitive disorder using a macaque model. The project examines how neuroinflammation, myeloid dysregulation, and blood-brain barrier decline drive cognitive impairment in aging and HIV infection. The research uses a macaque model...
- The National Institute on Aging awarded The Administrators of Tulane Educational Fund (Tulane University) $871,998 on August 1, 2026, under the Aging Research program (CFDA 93.866) to investigate accelerated aging in the central nervous system of SIV-infected macaques. The research focuses on astrocyte dysfunction as a central mechanism driving HIV-associated accelerated aging and cognitive decline. The study examines how activated astrocytes in brain regions increase leukocyte transmigration...
- The National Institute on Drug Abuse awarded the University of Alabama at Birmingham $1.765 million on April 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate how cannabis use impacts T cell phenotype, HIV seeding and persistence in the central nervous system, and neuropathogenesis in people living with HIV. The project, titled "The Impact of Substance Use on the Role of T Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis,"...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $746,063 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate amyloid beta plaque formation and neuroinflammation in aging people with HIV. The award funds exploration of cell-specific transcriptional changes associated with early amyloid beta deposition in human brain, distinguishing compacted amyloid with early neuritic pathology from diffuse amyloid without neuritic change, and...
- The National Institute on Aging awarded Tulane University four hundred twenty thousand seven hundred fifty dollars on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of L1 retrotransposons in normal brain aging and Alzheimer's disease in vivo. The research tests whether chronic L1 retrotransposon expression contributes to Alzheimer's disease progression using mouse models of L1 retrotransposition and Alzheimer's disease. L1 is a repetitive genetic...
- The National Institute on Drug Abuse awarded Duke University $731,879 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the impact of cannabis use on the inflammasome in people with HIV compared to HIV-seronegative persons. The research leverages biospecimens from a cohort of clinically and neurologically phenotyped HIV-infected cannabis users and non-users to determine how recreational cannabis use modulates the NLRP3 inflammasome and its effects on...
- The National Institute of Neurological Disorders and Stroke awarded Louisiana State University Health Sciences Center-Shreveport $582,172 on May 13, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate mechanistic interactions between viral infection and progression of Lewy pathology and dementia. The research examines neuropathological connections between COVID-19 and Alzheimer's disease and related dementias, focusing...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,233,586 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate epigenetic and neuroimmune mechanisms underlying cannabis-cannabinoid neuroimmunomodulation in people living with HIV. The recipient will conduct integrated clinical, postmortem, and mechanistic research examining how THC and CBD reshape the neuroimmune axis in people living with HIV through...
The National Institute on Aging awarded Louisiana State University Health Sciences Center New Orleans $748,679 on August 5, 2026, under the Aging Research program (CFDA 93.866) to conduct an autopsy-based study examining the anti-inflammatory effects of cannabis on Alzheimer's disease-associated neuropathology in people living with HIV. The recipient will analyze full-body autopsy tissues collected from decedents with and without HIV-1 to characterize HIV-1 tissue reservoirs, assess cannabis use effects on reservoir size and distribution, and investigate whether chronic HIV-1 infection accelerates Alzheimer's disease neuropathology. Preliminary findings from the existing tissue repository of 459 decedents indicate that HIV-1 tissue reservoirs were significantly reduced in cannabis users with corresponding decreases in pro-inflammatory cytokines, and that brain tissues from people living with HIV show increased Alzheimer's disease-associated tauopathy at younger ages than in uninfected individuals. The work will examine whether inflammation represents a key mechanism linking HIV-1 infection to early-onset Alzheimer's disease. Work is performed in New Orleans, Louisiana. The project period extends from August 5, 2026, through April 30, 2031. The award is classified as a Project Grant, the standard assistance type for NIH R01 awards supporting biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $748.7k | 8/3/26 |